Cargando…

Multiple doses of icatibant used during pregnancy

BACKGROUND: Hereditary angioedema (HAE) is a life-long disease that often manifests by puberty. Treatment of attacks is essential to improve quality of life and to decrease morbidity and mortality. During pregnancy, treatment is limited because multiple treatment options, including icatibant, are no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaminsky, Lauren W., Kelbel, Theodore, Ansary, Fay, Craig, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OceanSide Publications, Inc. 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662544/ https://www.ncbi.nlm.nih.gov/pubmed/29070276 http://dx.doi.org/10.2500/ar.2017.8.0210

Ejemplares similares

Review of icatibant use in the Winnipeg Regional Health Authority
por: Cai, George, et al.
Publicado: (2020)

Cohort experience of second messenger RNA vaccine dose tolerance after an initial-dose reaction
por: Eastman, Jacqueline, et al.
Publicado: (2022)

Hereditary angioedema: epidemiology, management, and role of icatibant
por: Ghazi, Aasia, et al.
Publicado: (2013)

87 Treatment of Idiopathic Nonhistaminergic Angiodema with Icatibant
por: Lleonart, Ramon, et al.
Publicado: (2012)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

A single-blind, randomized, crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain)
por: Takahagi, Shunsuke, et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Therapeutic trial in hereditary angioedema type III: Icatibant
por: Garro, Laila Sabino, et al.
Publicado: (2015)

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks
por: Longhurst, Hilary J., et al.
Publicado: (2016)

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study()
por: Grumach, Anete S., et al.
Publicado: (2022)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Icatibant in the Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
por: Crooks, Neil H., et al.
Publicado: (2014)

164 Treatment of Acquired Angioedema with the Bradykinin Receptor Antagonist Icatibant
por: Siani, Maria Concetta, et al.
Publicado: (2012)

Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant
por: Ho, Peter, et al.
Publicado: (2014)

Diagnosis and screening of patients with hereditary angioedema in primary care
por: Henao, Maria Paula, et al.
Publicado: (2016)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Icatibant as an early rescue therapy in hypovolemic shock with converting enzyme inhibitor treatment
por: Charbonneau, Hélène, et al.
Publicado: (2017)

Case report of treatment with Icatibant for recurrent throat swelling due to hereditary angioedema
por: Chung, Arthur G, et al.
Publicado: (2010)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries
por: Caballero, T., et al.
Publicado: (2017)

Long‐term safety of icatibant treatment of patients with angioedema in real‐world clinical practice
por: Zanichelli, A., et al.
Publicado: (2017)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
por: Longhurst, H. J., et al.
Publicado: (2017)

Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study
por: Campos, Regis Albuquerque, et al.
Publicado: (2014)

Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
por: Blasco, Antonio J, et al.
Publicado: (2013)

Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review
por: Yeung, Erin K., et al.
Publicado: (2018)

Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
por: Longhurst, Hilary J., et al.
Publicado: (2018)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

Icatibant, another piece of the therapeutic puzzle regarding hemodynamic side effects of angiotensin-converting enzyme inhibitors
por: Honore, Patrick M., et al.
Publicado: (2019)

Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant
por: Bouillet, Laurence, et al.
Publicado: (2017)

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II
por: Floccard, Bernard, et al.
Publicado: (2012)

454 Efficacy of Icatibant Versus Fresh Frozen Plasma for Attacks of Hereditary Angioedema: Analysis of Indivudual Symptoms by Attack Site
por: Lara, Alicia, et al.
Publicado: (2012)

Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain
por: Guilarte, Mar, et al.
Publicado: (2021)

Inhibition of bradykinin in SARS-CoV-2 infection: a randomised, double-blind trial of icatibant compared with placebo (ICASARS)
por: Bailey, Melanie, et al.
Publicado: (2023)

Self-administration of a novel subcutaneous bradykinin b(2) receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
por: Santucci, Stephanie, et al.
Publicado: (2014)

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
por: Bygum, Anette, et al.
Publicado: (2019)

A novel therapeutic concept for the treatment of acute angioedema attacks in hereditary angioedema patients: multiple successful treatments even in severe swelling attacks with the bradykinin-B2 receptor antagonist Icatibant
por: Bas, M, et al.
Publicado: (2006)

Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial
por: Malchair, Pierre, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_406o5q9g3jqbl740s6pustb620